MannKind (NASDAQ:MNKD) Stock Sees Buying Interest After An agreement With NRx Pharmaceuticals

August 4, 2021

NRx Pharmaceuticals (NASDAQ:NRXP) has signed an agreement with MannKind (NASDAQ:MNKD) to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human Vasoactive Intestinal Peptide (VIP), produced by the body to help protect cells against inflammatory conditions. Development will be based on MannKind’s Technosphere platform, that is the basis of the U.S. FDA-approved Afrezza inhaled insulin product. The investigational drug has demonstrated a greater than 2-fold increased odds…